中国肺癌杂志2012，Vol.15Issue(3)：179-182,4.DOI:10.3779/j.issn.1009-3419.2012.03.08
培美曲塞在晚期非小细胞肺癌二线及以上治疗中的疗效分析
Efficacy of Pemetrexed as Second-line Therapy or Beyond in Patients with Advanced Non-small Cell Lung Cancer
摘要
Abstract
Background and objective Pemetrexed is a standard second-line therapy in advanced non-small cell lung cancer (NSCLC). Currently, cytotoxic treatments beyond second-line therapy are not available. This study evaluated the efficacy and safety of pemetrexed as a salvage regimen in heavily pretreated patients with NSCLC. Methods Clinical data on 37 patients with advanced NSCLC who received pemetrexed as second-line therapy or beyond in Cancer Hospital of Peking Union Medical College from Feb 2005 to Sep 2009 were reviewed and analyzed retrospectively. Results Thirteen patients (35.1%) received pemetrexed as second-line treatment, whereas 24 (64.9%) received it as third-line treatment or beyond. Complete response, partial response, stable disease and progressive disease were noted in 1 (2.7%), 2 (5.4%), 17 (45.9%) and 12 (32.4%) of the patients, respectively, with the disease control rate being 54.1%. The median duration of progression free survival was 8.05 months, whereas that of overall survival was 19.29 months. Conclusion Pemetrexed is efficacious and tolerable as second-line therapy or beyond for advanced NSCLC and should thus be recommended for patients with this disease.关键词
肺肿瘤/培美曲塞/化疗Key words
Lung neoplasms/ Pemetrexed/ Chemotherapy分类
医药卫生引用本文复制引用
李峻岭,王静,郝学志,张湘茹,石远凯..培美曲塞在晚期非小细胞肺癌二线及以上治疗中的疗效分析[J].中国肺癌杂志,2012,15(3):179-182,4.基金项目
本研究受中央保健专项基金(No.B2009B12A)资助 （No.B2009B12A）
